Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Rating of “Hold” from Analysts

Shares of Invivyd, Inc. (NASDAQ:IVVD) have been assigned an average recommendation of “Hold” from the six ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $8.00.

IVVD has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Invivyd in a research report on Monday, June 15th. Wall Street Zen cut shares of Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a research note on Friday, July 24th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th.

Hedge Funds Weigh In On Invivyd

Institutional investors and hedge funds have recently bought and sold shares of the business. Perceptive Advisors LLC acquired a new stake in Invivyd in the 4th quarter valued at about $53,809,000. BVF Inc. IL acquired a new position in shares of Invivyd during the 4th quarter worth approximately $48,227,000. RA Capital Management L.P. acquired a new position in shares of Invivyd during the 3rd quarter worth approximately $18,831,000. ADAR1 Capital Management LLC purchased a new stake in shares of Invivyd in the third quarter valued at approximately $8,108,000. Finally, Janus Henderson Group PLC grew its position in shares of Invivyd by 28.2% in the fourth quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company’s stock valued at $80,870,000 after purchasing an additional 7,160,065 shares in the last quarter. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Stock Performance

NASDAQ:IVVD opened at $0.54 on Monday. Invivyd has a 12 month low of $0.48 and a 12 month high of $3.07. The stock has a 50 day moving average of $0.87 and a two-hundred day moving average of $1.36. The firm has a market cap of $157.62 million, a P/E ratio of -1.73 and a beta of 0.71.

Invivyd (NASDAQ:IVVD) last announced its earnings results on Thursday, May 14th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05). The firm had revenue of $13.74 million for the quarter, compared to analyst estimates of $18.04 million. Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%. On average, research analysts forecast that Invivyd will post -0.5 earnings per share for the current year.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.